Physician profile
Steven E Massad
NPI 1386095743
$1,254.75
in general payments reported to CMS, 2019-2025
21 companies · $169 in 2025
The $169 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $261 · 2022: $209 · 2023: $267 · 2024: $349 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $303.08 | 2021-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $161.37 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $146.69 | 2023-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $146.01 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Nevro Corp. | $77.37 | 2021 | |
| Corcept Therapeutics | $65.56 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $39.95 | 2021-2022 | |
| Grt US Holding, INC. | $36.14 | 2022 | |
| Merck Sharp & Dohme LLC | $35.94 | 2022-2024 | Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.98 | 2021-2025 | Xifaxan |
| Astellas Pharma US INC | $29.02 | 2023 | Veozah |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.05 | 2022 | |
| Exact Sciences Corporation | $21.02 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $18.33 | 2021 | |
| Boston Scientific Corporation | $18.01 | 2025 | General - Pain Management |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $17.36 | 2021 | |
| Radius Health, INC. | $17.06 | 2024 | Tymlos |
| Dexcom, INC. | $16.62 | 2024 | Dexcom G6 Transmitter |
| Baxter Healthcare | $14.90 | 2023 | Hillrom - Monarch Airway Clearance System |
| Sanofi Pasteur INC. | $14.23 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $14.06 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Massad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.